Neuraminidase activity assays for monitoring MDCK cell culture derived influenza virus

被引:59
作者
Nayak, DP
Reichl, U
机构
[1] Max Planck Inst Dynam Complex Tech Syst, D-39106 Magdeburg, Germany
[2] Lehrstuhl Bioprozesstech, D-39106 Magdeburg, Germany
关键词
tissue culture broth; downstream processing; influenza A virus; fluorometric; neuraminidase and TBA method;
D O I
10.1016/j.jviromet.2004.07.005
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Three assay methods were investigated for monitoring the time-course of neuraminidase (NA) activity of tissue culture derived equine influenza A virus from large-scale microcarrier cultivation and several steps of downstream processing required for the production of inactivated vaccines. Measurements of neuraminidase activity by a thiobarbituric acid (TBA) and a fluorometric method using Amplex Red as a fluorogen (FL-AR) did not correlate with the increase of hemagglutinin (HA) during virus replication. Samples analysed by the TBA method showed unspecific interference from low molecular weight compounds (<3 kDa) of cell growth medium and virus maintenance medium. Further investigations showed that this was probably caused by interfering reactions between reducing sugars and amino acids that can be overcome by dialysis of samples. On the other hand, the sensitivity of the FL-AR method was not sufficient for the required measuring range. However, a reliable and sensitive fluorometric assay method (FL-MU-NANA) was obtained using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid (4-MU-NANA) as a substrate, which allowed the detection of neuraminidase activities as low as 0.09 mU/mL. In this assay, time-course of neuraminidase activities correlated well with increasing hemagglutinin activities during virus replication in a bioreactor. Analysis of samples from various downstream processing steps comprising of clarification, inactivation, ultrafiltration (UF) and size-exclusion chromatography for the purification of influenza virus showed that neuraminidase activity was preserved at comparatively high levels. Based on the hemagglutinin and neuraminidase activity of the clarified and inactivated virus harvest, the overall recovery after gel filtration was about 34.4% and 119.5%, respectively. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:9 / 15
页数:7
相关论文
共 17 条
  • [1] AYMARDHENRY M, 1973, B WORLD HEALTH ORGAN, V48, P199
  • [2] INACTIVATION OF VIRAL-ANTIGENS FOR VACCINE PREPARATION WITH PARTICULAR REFERENCE TO THE APPLICATION OF BINARY ETHYLENIMINE
    BAHNEMANN, HG
    [J]. VACCINE, 1990, 8 (04) : 299 - 303
  • [3] Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies
    Barnett, JM
    Cadman, A
    Gor, D
    Dempsey, M
    Walters, M
    Candlin, A
    Tisdale, M
    Morley, PJ
    Owens, IJ
    Fenton, RJ
    Lewis, AP
    Claas, ECJ
    Rimmelzwaan, GF
    De Groot, R
    Osterhaus, ADME
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) : 78 - 87
  • [4] Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir
    Buxton, RC
    Edwards, B
    Juo, RR
    Voyta, JC
    Tisdale, M
    Bethell, RC
    [J]. ANALYTICAL BIOCHEMISTRY, 2000, 280 (02) : 291 - 300
  • [5] Metabolism of MDCK cells during cell growth and influenza virus production in large-scale microcarrier culture
    Genzel, Y
    Behrendt, I
    König, S
    Sann, H
    Reichl, U
    [J]. VACCINE, 2004, 22 (17-18) : 2202 - 2208
  • [6] Govorkova E A, 1999, Dev Biol Stand, V98, P39
  • [7] Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay
    Gubareva, LV
    Webster, RG
    Hayden, FG
    [J]. ANTIVIRAL RESEARCH, 2002, 53 (01) : 47 - 61
  • [8] Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en
    Gubareva, LV
    Robinson, MJ
    Bethell, RC
    Webster, RG
    [J]. JOURNAL OF VIROLOGY, 1997, 71 (05) : 3385 - 3390
  • [9] Development of a mammalian cell (Vero) derived candidate influenza virus vaccine
    Kistner, O
    Barrett, PN
    Mundt, W
    Reiter, M
    Schober-Bendixen, S
    Dorner, F
    [J]. VACCINE, 1998, 16 (9-10) : 960 - 968
  • [10] Lamb RA, 2001, FIELDS VIROLOGY, P1487, DOI DOI 10.1038/CR.2017.129